Managed care will continue to evolve and employers and policy makers have a responsibility to understand how to best serve ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by ...

New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.

The session follows the American Association for Cancer Research's prior call to action against executive orders that would ...

Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world ...

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of ...